GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » Cyclically Adjusted PB Ratio

THER (Theralink Technologies) Cyclically Adjusted PB Ratio : (As of May. 27, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Theralink Technologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Theralink Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralink Technologies Cyclically Adjusted PB Ratio Chart

Theralink Technologies Annual Data
Trend Feb14 Feb15 Dec16 Dec17 Dec18 Dec19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Theralink Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Theralink Technologies's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Theralink Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralink Technologies's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's Cyclically Adjusted PB Ratio falls into.


;
;

Theralink Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Theralink Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Theralink Technologies's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.009/129.4194*129.4194
=-0.009

Current CPI (Dec. 2023) = 129.4194.

Theralink Technologies Quarterly Data

Book Value per Share CPI Adj_Book
201402 -621.000 99.057 -811.349
201405 -714.000 100.373 -920.625
201408 -713.000 100.352 -919.521
201411 -1,060.000 99.635 -1,376.877
201502 -1,044.000 99.032 -1,364.350
201505 -6.750 100.333 -8.707
201508 -1.667 100.548 -2.146
201512 7.303 99.792 9.471
201603 2.316 100.470 2.983
201606 -4.364 101.688 -5.554
201609 -4.544 101.861 -5.773
201612 -10.210 101.863 -12.972
201703 10.714 102.862 13.480
201706 11.462 103.349 14.353
201709 -18.216 104.136 -22.639
201712 -65.242 104.011 -81.180
201803 -17.838 105.290 -21.926
201806 -31.728 106.317 -38.622
201809 -30.398 106.507 -36.937
201812 -22.870 105.998 -27.923
201903 -29.685 107.251 -35.821
201906 -30.495 108.070 -36.520
201909 -28.553 108.329 -34.112
201912 -19.086 108.420 -22.783
202003 -22.682 108.902 -26.955
202006 0.747 108.767 0.889
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 -0.001 111.754 -0.001
202106 -0.001 114.631 -0.001
202109 -0.001 115.734 -0.001
202112 -0.001 117.630 -0.001
202203 -0.001 121.301 -0.001
202206 -0.001 125.017 -0.001
202209 -0.001 125.227 -0.001
202212 -0.007 125.222 -0.007
202303 -0.009 127.348 -0.009
202306 -0.008 128.729 -0.008
202309 -0.006 129.860 -0.006
202312 -0.009 129.419 -0.009

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Theralink Technologies  (OTCPK:THER) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Theralink Technologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralink Technologies Business Description

Traded in Other Exchanges
N/A
Address
15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.
Executives
Danica Holley director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz director 15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors director 1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin director, officer: Chief Executive Officer HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc 10 percent owner 1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett officer: Chief Executive Officer 230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb director PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman 10 percent owner, officer: Chief Operating Officer-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme director, 10 percent owner, officer: Global Operations GM-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman director C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: CFO & President 549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head director, officer: Chief Executive Officer 6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817

Theralink Technologies Headlines

From GuruFocus

Theralink� Technologies Issues Letter to Shareholders

By PRNewswire PRNewswire 01-06-2021